Welcome to our dedicated page for Nevro news (Ticker: NVRO), a resource for investors and traders seeking the latest updates and insights on Nevro stock.
Nevro Corp. (NYSE: NVRO) is a global medical device company headquartered in Redwood City, California and focused on technologies for chronic pain treatment. This news page aggregates company announcements, financial updates and clinical evidence related to Nevro’s proprietary 10 kHz spinal cord stimulation (SCS) therapy and sacroiliac (SI) joint fusion offerings.
Investors and observers can follow Nevro’s regular disclosures on quarterly and full-year financial results, including worldwide and U.S. revenue, international revenue, operating performance and cash position. The company also issues updates on strategic matters, such as its announced definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction, which remains subject to shareholder and regulatory approvals and other customary conditions.
Because Nevro operates in chronic pain management, a significant portion of its news flow highlights clinical and product developments. These include publications of data on 10 kHz SCS in painful diabetic neuropathy and Type 2 diabetes, showing durable pain relief and reported improvements in measures such as HbA1c, weight and sleep, as well as biomechanical studies of the Nevro1 SI Joint Fusion System. Product and regulatory updates, such as CE Mark Certification in Europe for the HFX iQ SCS system and launches of HFX iQ with HFX AdaptivAI, also feature prominently.
In addition, Nevro regularly announces employee inducement equity awards under NYSE Rule 303A.08, reflecting hiring activity, and provides commentary on commercial execution, restructuring efforts and marketing initiatives. For anyone tracking NVRO, this news feed offers a centralized view of Nevro’s financial performance, clinical evidence, product expansion and corporate transactions over time.
Nevro Corp. (NYSE: NVRO), a leader in innovative medical devices for chronic pain, announced that CEO D. Keith Grossman will participate in Citi Bank's Head Shoulders Knees and Toes Conference Call Series on November 30, 2020, at 2 pm ET. Investors can join the call by dialing (856) 344-9142 with Conference ID: 3168278. Nevro's Senza spinal cord stimulation system has shown success in reducing opioid use in over 65% of patients, highlighting its effectiveness in chronic pain treatment. For more details, visit www.nevro.com.
Nevro Corp. (NYSE: NVRO) announced the acceptance of data abstracts for Painful Diabetic Neuropathy (PDN) and Non-Surgical Refractory Back Pain (NSRBP) at the NANS 2021 conference, scheduled for January 15, 2021. The PDN trial, the largest randomized controlled trial of spinal cord stimulation (SCS) treatment, will feature 216 subjects and reveal new 12-month pain relief data. The NSRBP study includes 159 participants, presenting its primary endpoint results. Nevro's CEO D. Keith Grossman will hold a virtual investor briefing for updates and Q&A following the presentations.
Nevro Corp. (NVRO) reported Q3 2020 financial results with worldwide revenue of $108.5 million, marking an 8% increase year-over-year and a 92% sequential increase from Q2 2020. U.S. revenue also rose by 8% to $90.9 million. Gross profit improved by 9% to $76.1 million, with a gross margin of 70.1%. Operating expenses decreased by 7% to $79.6 million. The net loss narrowed significantly to $3.5 million, an 78% improvement year-over-year. Nevro is advancing its clinical studies in diabetic neuropathy and back pain, with submissions planned for the FDA.
Nevro Corp. (NYSE: NVRO), a leader in chronic pain treatment, will announce its Q3 financial results on November 5, 2020, after market close. The results will be discussed in a conference call at 1:30 PM PT/4:30 PM ET, accessible via dial-in or webcast. Nevro's Senza spinal cord stimulation system offers innovative non-drug therapies, significantly reducing or eliminating opioid use in over 65% of patients. This event is critical for investors monitoring Nevro's financial performance and future outlook.
Nevro Corp. (NYSE: NVRO) announced plans to establish global manufacturing operations in Costa Rica to enhance growth. The company has secured a 10-year lease for a 35,000 square foot facility, with projected capital expenditures of approximately $11 million from 2020-2023, alongside an additional $10 million in implementation costs. This initiative aims to optimize their cost structure and improve gross margins following validation in 2022. CEO Keith Grossman emphasized the shift from outsourced manufacturing to in-sourcing for increased efficiency.
Nevro Corp. (NYSE: NVRO) announced that Keith Grossman, its Chairman and CEO, will present at two major healthcare conferences. These include the Wells Fargo 2020 Virtual Healthcare Conference on September 9, 2020, at 4:00 PM ET, and the Morgan Stanley 18th Annual Global Healthcare Conference on September 14, 2020, at 3:00 PM ET. Live webcasts will be available on Nevro’s website, with replays accessible for 14 days. Nevro specializes in innovative solutions for chronic pain management, notably through its Senza spinal cord stimulation system.
Nevro Corp. (NYSE: NVRO), a medical device company focused on chronic pain solutions, will present at the Canaccord Genuity 40th Annual Virtual Growth Conference on August 13, 2020, at 3:30 PM ET. CEO D. Keith Grossman will lead the presentation. A live webcast can be accessed on Nevro's website, with a replay available for 30 days afterward. Nevro's innovative Senza spinal cord stimulation system provides a non-pharmacologic approach to managing chronic pain, showing that HF10 therapy can reduce or eliminate opioids in over 65% of patients in clinical studies.
Nevro Corp. (NYSE: NVRO) reported a 40% decline in worldwide revenue for Q2 2020, totaling $56.4 million, primarily due to COVID-19 restrictions affecting elective surgeries. U.S. revenue fell 35% to $51.0 million, with a 37% drop in trials and a 34% drop in permanent implants. International revenue also suffered, decreasing 65% to $5.4 million. Gross profit was $35.3 million, reflecting a 45% decrease year-over-year. Operating expenses decreased 22% to $70.6 million. The company holds $562.3 million in cash and equivalents as of June 30, 2020.
Nevro Corp. (NYSE: NVRO) plans to release its financial results for Q2 2020 on August 5, 2020, after market close. A conference call will follow at 1:30 pm PT to discuss these results. Investors can access the call by dialing (833) 968-2321 in the U.S. or +1 (778) 560-2840 internationally, using Conference ID: 8783575. Nevro is a global medical device company specializing in innovative solutions for chronic pain management, notably through its proprietary HF10 therapy, which has shown a significant ability to reduce opioid usage.